# Asthma & COPD Drug Ref

> Asthma & COPD Drug Ref (iPhone/iPad app by ATIF ELNIL.)

- Source: https://appshunter.io/ios/app/asthma-and-copd-drug-ref/id6761284070 (this page in markdown: same URL + `.md`)
- Developer: [ATIF ELNIL](https://appshunter.io/developer/1886307011)
- Category: Medical, Education
- Price: $9.99 (on sale, was $14.99)
- Age rating: 17+
- Requires: iOS 16 · 1 MB
- Languages: English
- Released: 2026-04-01
- Data updated: 2026-05-15
- User reviews in markdown: https://appshunter.io/ios/app/asthma-and-copd-drug-ref/id6761284070/reviews.md

## What is Asthma & COPD Drug Ref?

IMPORTANT: This app is intended for use by qualified healthcare professionals only. Always seek the advice of a qualified clinician before making any medical or prescribing decisions.

Asthma & COPD Drug Ref is a comprehensive evidence-based respiratory pharmacology reference for doctors, nurses, pharmacists and respiratory specialist nurses. Built for the clinic, ward and emergency department.

DRUG CLASSES REFERENCE
Complete inhaled and oral drug reference across 6 classes:
- SABA: salbutamol, terbutaline — doses, acute and routine use
- LABA: salmeterol, formoterol, indacaterol, vilanterol, olodaterol
- LAMA: tiotropium, umeclidinium, glycopyrronium, aclidinium, ipratropium
- ICS: beclometasone, budesonide, fluticasone propionate and furoate, ciclesonide
- Combination inhalers: ICS/LABA, LABA/LAMA, and triple therapy (ICS/LABA/LAMA)
- Other agents: montelukast, theophylline, roflumilast, cromones

STEP THERAPY
- GINA 2024: 5-step asthma treatment ladder with as-needed ICS/formoterol guidance
- GOLD 2024: ABCE group framework and pharmacological escalation strategy
- Step-up and step-down criteria with review intervals

BIOLOGIC THERAPY
7 approved biologics with eligibility criteria, NICE TA references and dosing:
- Omalizumab (NICE TA278) — anti-IgE, allergic asthma
- Mepolizumab (NICE TA431) — anti-IL-5, eosinophilic asthma
- Benralizumab (NICE TA565) — anti-IL-5 receptor
- Dupilumab (NICE TA751) — anti-IL-4/IL-13, broadest T2 indication
- Tezepelumab (NICE TA878) — anti-TSLP, effective in T2-low asthma
- Reslizumab — IV anti-IL-5
- Dupilumab for COPD (2024) — BOREAS/NOTUS trials

ACUTE MANAGEMENT
- Acute severe asthma: severity classification (moderate/severe/life-threatening/near-fatal)
- 7-step treatment protocol including IV magnesium, IV salbutamol, ICU referral criteria
- COPD exacerbation: controlled oxygen, NIV (BIPAP) criteria and settings
- Antibiotic guidance — evidence-based indications

INHALER GUIDE
- pMDI, DPI, soft mist inhaler (Respimat) and nebuliser technique
- Spacer devices — indications, cleaning, replacement
- Device selection guide including environmental considerations (NICE NG80)

OXYGEN THERAPY
- SpO2 targets by condition — including COPD controlled oxygen 88–92%
- Delivery devices: nasal cannula, Venturi mask, non-rebreather, HFNO, NIV
- Long-term oxygen therapy (LTOT) criteria — NICE NG115

GINA & GOLD 2024 GUIDELINES
- Asthma diagnosis, control assessment (ACQ/ACT), key GINA 2024 recommendations
- GOLD ABCD groups, spirometric grading, non-pharmacological management
- Asthma vs COPD comparison table

SPECIAL SITUATIONS
- Pregnancy: safe and unsafe drugs, acute asthma management in pregnancy
- Elderly: device considerations, polypharmacy interactions, spirometry
- Occupational asthma: causes, diagnosis, RIDDOR reporting
- Difficult/severe asthma: distinguishing difficult-to-treat from true severe asthma

SOURCES AND REFERENCES
Full tappable reference list: GINA 2024, GOLD 2024, BTS/SIGN 2019, NICE NG115, NICE TA278/431/565/751/878, NAVIGATOR trial, UPLIFT, IMPACT, BOREAS, BTS oxygen guidelines and BNF.

DISCLAIMER
This app is intended for use by qualified healthcare professionals only as a clinical decision-support and educational reference tool. It is not a medical device and does not replace individual clinical assessment, local guidelines, or official prescribing information.

Dr Atif Elnil MBBS MRCP UK, St Georges Hospital London


## Version history (last 2 releases)

### 1.0.1 — 2026-05-05

Improved font size. new privacy policy link.

### 1.0 — 2026-04-01

No release notes.

## More apps by ATIF ELNIL

- [Antiseizure Medications](https://appshunter.io/ios/app/antiseizure-medications/id6760823031)
- [NIHSS Calculator](https://appshunter.io/ios/app/nihss-calculator/id6760891744)
- [HyperRef Clinical](https://appshunter.io/ios/app/hyperref-clinical/id6760921930)
- [PD Drug Reference](https://appshunter.io/ios/app/pd-drug-reference/id6760972673)
- [MS DMT Reference](https://appshunter.io/ios/app/ms-dmt-reference/id6761038062)
- [ElectroBalance Pro](https://appshunter.io/ios/app/electrobalance-pro/id6761238034)

All apps by ATIF ELNIL: https://appshunter.io/developer/1886307011

---

*Data collected daily from the US App Store and indexed by [AppsHunter](https://appshunter.io/). User reviews are verbatim App Store reviews. Ratings, prices and chart positions refresh continuously; this snapshot is from 2026-05-15.*